A phase II trial of GDC-0084 for Glioblastoma.

Trial Profile

A phase II trial of GDC-0084 for Glioblastoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs GDC 0084 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2018 According to a Kazia Therapeutics media release, an initial data read-out is anticipated in early calendar 2019.
    • 28 Mar 2018 According to a Kazia Therapeutics media release, this study has been approved by Western Institutional Review Board in November 2017.
    • 28 Mar 2018 According to a Kazia Therapeutics media release, first site, Stephenson Cancer Center at the University of Oklahoma, has been initiated and will begin screening patients after the Easter holidays.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top